Clinical Trial Update: Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial updating the addition of pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) for stage III-IV or recurrent endometrial cancer; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• KEYTRUDA (PEMBROLIZUMAB)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-18